vs
CBIZ, Inc.（CBZ）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
CBIZ, Inc.的季度营收约是Revvity的1.1倍（$848.6M vs $772.1M），CBIZ, Inc.净利率更高（19.0% vs 12.7%，领先6.3%），Revvity同比增速更快（5.9% vs 1.3%），Revvity自由现金流更多（$161.8M vs $-28.5M），过去两年CBIZ, Inc.的营收复合增速更高（42.1% vs 9.0%）
CBIZ, Inc.是美国知名的金融、保险及咨询服务提供商，总部位于俄亥俄州独立市，为美国规模最大的会计、保险经纪、金融与咨询服务机构之一。集团在全美设有120多个办事处，拥有近7000名员工，1996年起在纽交所上市，1997年起使用股票代码CBZ交易。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CBZ vs RVTY — 直观对比
营收规模更大
CBZ
是对方的1.1倍
$772.1M
营收增速更快
RVTY
高出4.6%
1.3%
净利率更高
CBZ
高出6.3%
12.7%
自由现金流更多
RVTY
多$190.3M
$-28.5M
两年增速更快
CBZ
近两年复合增速
9.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $848.6M | $772.1M |
| 净利润 | $161.6M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 23.2% | 14.5% |
| 净利率 | 19.0% | 12.7% |
| 营收同比 | 1.3% | 5.9% |
| 净利润同比 | — | 3.9% |
| 每股收益（稀释后） | $2.63 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CBZRVTY
| Q1 26 | $848.6M | — | ||
| Q4 25 | $542.7M | $772.1M | ||
| Q3 25 | $693.8M | $698.9M | ||
| Q2 25 | $683.5M | $720.3M | ||
| Q1 25 | $838.0M | $664.8M | ||
| Q4 24 | $460.3M | $729.4M | ||
| Q3 24 | $438.9M | $684.0M | ||
| Q2 24 | $420.0M | $691.7M |
净利润CBZRVTY
| Q1 26 | $161.6M | — | ||
| Q4 25 | $-79.4M | $98.4M | ||
| Q3 25 | $30.1M | $46.7M | ||
| Q2 25 | $41.9M | $53.9M | ||
| Q1 25 | $122.8M | $42.2M | ||
| Q4 24 | $-90.7M | $94.6M | ||
| Q3 24 | $35.1M | $94.4M | ||
| Q2 24 | $19.8M | $55.4M |
毛利率CBZRVTY
| Q1 26 | — | — | ||
| Q4 25 | -9.4% | — | ||
| Q3 25 | 13.0% | 53.6% | ||
| Q2 25 | 12.9% | 54.5% | ||
| Q1 25 | 27.2% | 56.5% | ||
| Q4 24 | -13.4% | — | ||
| Q3 24 | 16.6% | 56.3% | ||
| Q2 24 | 12.8% | 55.7% |
营业利润率CBZRVTY
| Q1 26 | 23.2% | — | ||
| Q4 25 | -15.7% | 14.5% | ||
| Q3 25 | 8.5% | 11.7% | ||
| Q2 25 | 8.8% | 12.6% | ||
| Q1 25 | 23.9% | 10.9% | ||
| Q4 24 | -23.2% | 16.3% | ||
| Q3 24 | 11.3% | 14.3% | ||
| Q2 24 | 7.5% | 12.4% |
净利率CBZRVTY
| Q1 26 | 19.0% | — | ||
| Q4 25 | -14.6% | 12.7% | ||
| Q3 25 | 4.3% | 6.7% | ||
| Q2 25 | 6.1% | 7.5% | ||
| Q1 25 | 14.7% | 6.4% | ||
| Q4 24 | -19.7% | 13.0% | ||
| Q3 24 | 8.0% | 13.8% | ||
| Q2 24 | 4.7% | 8.0% |
每股收益（稀释后）CBZRVTY
| Q1 26 | $2.63 | — | ||
| Q4 25 | $-1.22 | $0.86 | ||
| Q3 25 | $0.48 | $0.40 | ||
| Q2 25 | $0.66 | $0.46 | ||
| Q1 25 | $1.91 | $0.35 | ||
| Q4 24 | $-1.84 | $0.77 | ||
| Q3 24 | $0.70 | $0.77 | ||
| Q2 24 | $0.39 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $28.7M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.9B | $7.3B |
| 总资产 | $4.6B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CBZRVTY
| Q1 26 | $28.7M | — | ||
| Q4 25 | $18.3M | $919.9M | ||
| Q3 25 | $17.0M | $931.4M | ||
| Q2 25 | $39.8M | $991.8M | ||
| Q1 25 | $8.8M | $1.1B | ||
| Q4 24 | $13.8M | $1.2B | ||
| Q3 24 | $1.1M | $1.2B | ||
| Q2 24 | $1.1M | $2.0B |
股东权益CBZRVTY
| Q1 26 | $1.9B | — | ||
| Q4 25 | $1.8B | $7.3B | ||
| Q3 25 | $1.9B | $7.4B | ||
| Q2 25 | $1.9B | $7.6B | ||
| Q1 25 | $1.9B | $7.6B | ||
| Q4 24 | $1.8B | $7.7B | ||
| Q3 24 | $927.9M | $7.9B | ||
| Q2 24 | $891.4M | $7.9B |
总资产CBZRVTY
| Q1 26 | $4.6B | — | ||
| Q4 25 | $4.4B | $12.2B | ||
| Q3 25 | $4.5B | $12.1B | ||
| Q2 25 | $4.5B | $12.4B | ||
| Q1 25 | $4.6B | $12.4B | ||
| Q4 24 | $4.5B | $12.4B | ||
| Q3 24 | $2.1B | $12.8B | ||
| Q2 24 | $2.2B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-25.5M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-28.5M | $161.8M |
| 自由现金流率自由现金流/营收 | -3.4% | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | -0.16× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $240.5M | $509.4M |
8季度趋势，按日历期对齐
经营现金流CBZRVTY
| Q1 26 | $-25.5M | — | ||
| Q4 25 | $143.6M | $182.0M | ||
| Q3 25 | $24.0M | $138.5M | ||
| Q2 25 | $113.1M | $134.3M | ||
| Q1 25 | $-88.3M | $128.2M | ||
| Q4 24 | $55.5M | $174.2M | ||
| Q3 24 | $43.7M | $147.9M | ||
| Q2 24 | $88.2M | $158.6M |
自由现金流CBZRVTY
| Q1 26 | $-28.5M | — | ||
| Q4 25 | $141.7M | $161.8M | ||
| Q3 25 | $22.1M | $120.0M | ||
| Q2 25 | $105.2M | $115.5M | ||
| Q1 25 | $-93.4M | $112.2M | ||
| Q4 24 | $52.3M | $149.8M | ||
| Q3 24 | $41.1M | $125.6M | ||
| Q2 24 | $86.3M | $136.6M |
自由现金流率CBZRVTY
| Q1 26 | -3.4% | — | ||
| Q4 25 | 26.1% | 21.0% | ||
| Q3 25 | 3.2% | 17.2% | ||
| Q2 25 | 15.4% | 16.0% | ||
| Q1 25 | -11.2% | 16.9% | ||
| Q4 24 | 11.4% | 20.5% | ||
| Q3 24 | 9.4% | 18.4% | ||
| Q2 24 | 20.5% | 19.7% |
资本支出强度CBZRVTY
| Q1 26 | — | — | ||
| Q4 25 | 0.4% | 2.6% | ||
| Q3 25 | 0.3% | 2.6% | ||
| Q2 25 | 1.2% | 2.6% | ||
| Q1 25 | 0.6% | 2.4% | ||
| Q4 24 | 0.7% | 3.4% | ||
| Q3 24 | 0.6% | 3.3% | ||
| Q2 24 | 0.4% | 3.2% |
现金转化率CBZRVTY
| Q1 26 | -0.16× | — | ||
| Q4 25 | — | 1.85× | ||
| Q3 25 | 0.79× | 2.97× | ||
| Q2 25 | 2.70× | 2.49× | ||
| Q1 25 | -0.72× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 1.25× | 1.57× | ||
| Q2 24 | 4.45× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CBZ
| Financial Services (1) | $740.3M | 87% |
| Benefits and Insurance Services | $108.2M | 13% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
